Abstract

Hinge Health, Inc. will release its quarterly results on February 10, 2026, Post Market, with investors watching revenue, margins, and EPS momentum amid improving profitability trends and ongoing execution on healthcare software growth.

Market Forecast

Based on the company’s latest guidance framework and available consensus-style estimates, this quarter’s revenue is projected at USD 156.64 million, with gross profit margin near recent levels at 81.86%, net profit margin expected to improve from last quarter’s -1.20%, and adjusted EPS estimated at USD 0.39, reflecting improving year-over-year momentum. Hinge Health, Inc.’s main business, Healthcare Software, is expected to maintain resilient demand from enterprise and payer channels, while continued commercialization supports stable pricing and robust renewal activity. The most promising segment is Healthcare Software with revenue forecast at USD 156.64 million, up 8.19% year-over-year, supported by increased client deployments and expanded digital MSK solutions.

Last Quarter Review

The previous quarter delivered revenue of USD 154.21 million, gross margin of 81.86%, GAAP net profit attributable to the parent company of USD -1.84 million, net profit margin of -1.20%, and adjusted EPS of USD 0.44. The quarter’s highlight was stronger-than-expected operating performance, with EBIT at USD 30.38 million versus estimates of USD 19.46 million, indicating disciplined cost control and scale efficiencies. Main business highlights showed Healthcare Software revenue at USD 154.21 million with continued portfolio breadth across digital musculoskeletal programs and employer/payer adoption supported by improved outcomes; year-over-year growth was not disclosed.

Current Quarter Outlook

Main Business: Healthcare Software

Hinge Health, Inc.’s Healthcare Software remains the core revenue engine, driven by digital musculoskeletal solutions, virtual physical therapy, and integrated care pathways for employers and health plans. With revenue forecast at USD 156.64 million and adjusted EPS at USD 0.39, the setup suggests a balanced expansion supported by contract renewals and upsell into broader MSK programs. Gross margin stability near 81.86% reflects a software-driven cost structure, with unit economics benefiting from higher platform utilization and automation across onboarding and care delivery. Management attention appears focused on maintaining retention and expanding average contract value through feature enhancement and clinical outcomes validation, which could underpin steady top-line growth and incremental operating leverage.

Most Promising Business: Digital MSK Expansion

The most promising revenue driver within Healthcare Software is the continued expansion of digital musculoskeletal care offerings, which include at-home therapy, connected devices, and data-driven care navigation. The forecast indicates revenue momentum at USD 156.64 million, up 8.19% year-over-year, aligned with broader employer adoption of value-based digital health solutions and payer integration for MSK benefits. Success will hinge on strengthening clinical evidence to reduce medical costs, maintaining user engagement, and layering chronic pain management modules, which together support sustained demand and justify pricing. Operational scalability—balancing care team capacity with growing member volumes—remains critical to preserve gross margin and move net margin into positive territory.

Key Stock Price Drivers This Quarter

Three factors appear most material to the stock’s near-term movement: revenue delivery versus the USD 156.64 million estimate, margin trajectory relative to the prior quarter’s -1.20% net margin, and EPS performance versus USD 0.39. A beat on revenue and EPS, alongside a sequential improvement in net margin, would validate operating leverage and underpin valuation stability. Conversely, any signs of churn or slower new-logo bookings could challenge the growth narrative, while unexpected expense pressure—particularly around care delivery and sales—would cap EPS upside. Investor attention will also be on visibility into second-half pipeline and any color on payer partnerships that could accelerate member acquisition without diluting economics.

Analyst Opinions

Across recent institutional commentary and previews, the balance of opinions trends cautiously positive, emphasizing revenue resilience and improving profitability while acknowledging execution risks. Previews point to potential upside if Hinge Health, Inc. maintains gross margin near 81.86% and delivers adjusted EPS close to USD 0.39 on USD 156.64 million revenue. Analysts highlight the stronger prior-quarter EBIT performance and EPS surprise as signals of operating discipline and maturing scale effects, an impetus for modestly bullish expectations into February 10, 2026, Post Market. The majority view favors a constructive stance on near-term results, conditioned on stable demand from employers and payers and a credible path toward sustained positive net margins.